Hamm John M. 4

What Happened

• John M. Hamm, Chief Financial Officer of Cumberland Pharmaceuticals (CPIX), was granted 3,000 shares as an award on March 18, 2026. The filing reports an acquisition price of $2.80 per share, for a total reported value of $8,400. The transaction is reported as a derivative award (transaction code A), indicating a grant or other compensation-related acquisition rather than an open-market purchase.

Key Details

• Transaction date and terms: 3,000 shares awarded on 2026-03-18 at $2.80 per share (total $8,400).
• Transaction type: Award / grant of derivative securities (code A).
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnotes/plans: No 10b5-1 plan, tax-withholding, or other special footnotes were disclosed in the filing.
• Timeliness: Form 4 was filed on 2026-03-20. This appears to be a timely filing (within the typical two-business-day reporting window).

Context

• Awards of derivative securities are typically compensation-related; they are not the same as open-market purchases and do not necessarily signal immediate personal bullish buying. Retail investors should view this as an insider compensation event unless the filing specifies vesting, sale, or exercise details.